Legend Biotech (LEGN) Competitors

Beigene (NASDAQ:ONC) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.

Is ONC or LEGN more profitable?

Beigene has a net margin of -25.94% compared to Legend Biotech's net margin of -66.92%. Beigene's return on equity of -25.12% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Legend Biotech	-66.92%	-29.69%	-19.45%

Does the MarketBeat Community believe in ONC or LEGN?

Legend Biotech received 83 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 72.13% of users gave Legend Biotech an outperform vote while only 62.50% of users gave Beigene an outperform vote.

Company	Underperform	Outperform
Beigene	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%
Legend Biotech	Outperform Votes 88 72.13%	Underperform Votes 34 27.87%

Do analysts rate ONC or LEGN?

Beigene currently has a consensus price target of $316.67, suggesting a potential upside of 32.45%. Legend Biotech has a consensus price target of $79.00, suggesting a potential upside of 145.57%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Beigene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Legend Biotech	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the media favor ONC or LEGN?

In the previous week, Legend Biotech had 1 more articles in the media than Beigene. MarketBeat recorded 15 mentions for Legend Biotech and 14 mentions for Beigene. Legend Biotech's average media sentiment score of 1.28 beat Beigene's score of 0.54 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beigene	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, ONC or LEGN?

Legend Biotech has lower revenue, but higher earnings than Beigene. Legend Biotech is trading at a lower price-to-earnings ratio than Beigene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beigene	$3.81B	6.19	-$881.71M	-$6.14	-38.94
Legend Biotech	$627.24M	9.42	-$518.25M	-$0.48	-67.02

Do institutionals and insiders believe in ONC or LEGN?

48.5% of Beigene shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 7.4% of Beigene shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk and volatility, ONC or LEGN?

Beigene has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Summary

Legend Biotech beats Beigene on 10 of the 18 factors compared between the two stocks.